we already knew everything which was stated in the abstract.
they said 12+ months which is what we had in november, 12.5 months. no different, but what if they were really alluding to 18 months? that is 12+ months, isn't it?

i'm believe they will elaborate and discuss what happened following the close of the trial in november, in the presentation on June 6-7. drD on YMB has said LL continued to be administered as per schedule.

16 of the 28 patients were the compassionate use patients. They already failed 2 other treatments. These people were very sick. But, yet, LL squeezed at least another 12+ months on average out of them.

More than likely, all of the 16 compassionate patients would have died had it not been for LL. Were these patients still very sick in november, at end of trial, or were they improved? The last 2 lines in the quote seem to suggest all treated with LL were on a road to recovery.

Therefore, why wouldn't they have continued LL to see what would happen so possibly, if these patients did survive and we were able to claim an OS of 18 months, wouldn't we have a better chance of getting BTD now? What is CytoDyn doing? Were people too sick to continue the drug? CytoDyn did not impose the halting of LL for mTNBC, only a partial hold on HIV and Covid.

Check out the exchange of comments in this Reddit post:
https://www.reddit.com/r/LeronLimab_Times/com...ying_dead/

What does Scott Kelly mean by this statement?

Quote:

---

"But there’s a very high bar for a breakthrough designation, and we don’t believe that’s enough data. So we will be progressing this molecule forward for mTNBC and looking for more development opportunities."

---